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Abstract
Introduction: The relationship between galectin-3 and diabetes mellitus or renal function has recently been investigated. In this study, 
we tried to evaluate the association of galectin-3 in urinary albumin excretion levels in type 2 diabetic patients.
Material and methods: In a group of 137 type 2 diabetes patients, the mean of the last three urinary microalbumin/creatinine ratios and 
galectin-3 levels were evaluated. The patient group was divided into three subgroups according to their level of albuminuria calculated 
with urine microalbumin/creatinine ratio.
Results: There was no significant difference between the galectin values of the three subgroups. Significant differences were observed 
between GFR results of group 1 vs. 3 (p < 0.0001) and group 2 vs. 3 (p = 0.0006), and serum creatinine results of group 1 vs. 3 (p = 0.0003) 
and group 2 vs. 3 (p < 0.0001). The three subgroups did not reveal any significant difference concerning the age, BMI, duration of DM, 
FPG, and HbA1c levels.
Conclusions: We concluded that serum galectin-3 values are not affected by the levels of urinary albumin excretion in DM patients. We 
could not find any relation between galectin-3 and the parameters of DM such as FPG, HbA1c, and duration of the disease. 
(Endokrynol Pol 2016; 67 (6): 580–584)
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Streszczenie
Wstęp: W ostatnim czasie badano związek między galektyną-3 a cukrzycą i czynnością nerek. Autorzy niniejszego badania podjęli próbę 
oceny związku galektyny-3 z wydalaniem albumin przez nerki u chorych na cukrzycę typu 2.
Materiał i metody: W grupie 137 chorych na cukrzycę typu 2 obliczono średnią ostatnich trzech współczynników mikroalbuminy/ 
/kreatynina w moczu oraz pomiarów stężeń galektyny-3. Chorych podzielono na trzy podgrupy w zależności od nasilenia albuminuria 
określonego na podstawie współczynnika mikroalbuminy/kreatynina w moczu.
Wyniki: Nie stwierdzono istotnych różnic pod względem stężeń galektyny między trzema podgrupami. Odnotowano natomiast istotne 
różnice wartości GFR między grupą 1 i 3 (p < 0,0001) oraz grupą 2 i 3 (p = 0,0006) oraz stężeń kreatyniny między grupą 1 i 3 (p = 0,0003) 
oraz grupą 2 i 3 (p < 0,0001). Podgrupy nie różniły się istotnie pod względem wieku, BMI, czasu trwania cukrzycy, FPG ani odsetka HbA1c.
Wnioski: Autorzy wykazali, że stężenia galektyny-3 w surowicy nie zależą od nasilenia wydalania albumin z moczem u chorych na cu-
krzycę. Nie stwierdzono zależności między stężeniem galektyny-3 a parametrami charakteryzującymi cukrzycę, takimi jak FPG, HbA1c, 
czas trwania choroby. (Endokrynol Pol 2016; 67 (6): 580–584)
Słowa kluczowe: galektyna-3; cukrzyca typu 2; nefropatia
Introduction
Nephropathy is one of the major complications of 
diabetes mellitus. Hyperglycaemia plays the central 
role in the development of diabetic complications. The 
biochemical abnormalities include increased polyol 
and hexosamine pathway activity, oxidative stress, 
advanced glycated end products (AGE’s) formation, 
and protein kinase C activation [1]. These abnormalities 
modify the function of the vascular cells and impair the 
physiological turnover of the vessel wall, resulting in 
target tissue dysfunction. In the case of nephropathy, 
the hallmark is an abnormal accumulation of extracel-
lular matrix inside the mesangium [1]. AGE biological 
effects in this process occur via a receptor-mediated 
pathway. These effects include downstream signalling 
and transcriptional events, which play a pivotal role in 
modulating target tissue injury in diabetes [2]. 
Galectin-3 is a member of the lectin family of 
carbohydrate-binding proteins. The molecule includes 
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a C-terminal carbohydrate recognition domain (CRD) 
with highly conserved residues between family mem-
bers and an N-terminal domain with a unique short end 
into an intervening proline-alanine-glycine-tyrosine re-
peat motif [3]. Galectin-3 localises intra- or extracellular-
ly. Extracellular galectin-3 interacts via the CRD with the 
b-galactoside residues of extracellular matrix and 
cell surface glycoproteins. Conversely, interactions 
of intracellular galectin-3 occur via peptide-peptide 
associations mediated by its N-terminus domain [2]. 
These structure and localisation properties of galec-
tin-3 explain its functions in broad-spectrum biological 
events in several disease conditions [4]. The intracellular 
effects include pre-mRNA splicing activity, cell control 
(proliferation, growth and differentiation) and protec-
tion from apoptosis. On the other hand, extracellular 
galectin-3 regulates cell adhesion, takes part in the 
modulation of immune/inflammatory function, and 
acts as an AGE receptor [5]. In a study performed on 
mice, galectin-3 ablation accelerated diabetes-induced 
glomerulopathy with glomerular lesions, significant 
albuminuria, and mesangial expansion, which are the 
functional and structural hallmarks of diabetic glomeru-
lopathy [6]. It is postulated that galectin-3 is upregulated 
in diabetes and aging because of increased AGE levels; 
thus it prevents AGE-induced tissue injury [2]. Besides, 
a more recent study revealed that galectin-3 might be 
involved in the regulation of glucose homeostasis by 
acting at the level of adipose tissue and pancreatic 
islets; it is thus participating in the pathogenesis of 
obesity and type 2 diabetes [7]. In a clinical study, it 
was found that in Type 2 diabetes patients, circulating 
levels of galectin-3 positively correlated with body mass 
index (BMI) and negatively correlated with glycated 
haemoglobin [8]. 
Urinary albumin secretion is the main tool for de-
tection and follow-up of the development of diabetic 
nephropathy. Taking into consideration the involve-
ment of galectin-3 in diabetes-induced nephropathy, 
we hypothesise that this molecule could have a rela-
tion with urinary albumin excretion. We thereby tried 
to evaluate the association of galectin-3 with urinary 
albumin excretion levels in type 2 diabetic patients in 
this present study. 
Material and methods
Study design
A total of 137 Type 2 diabetic patients (57 male, 
80 female) followed by the endocrinology department 
of our hospital were enrolled in the study. According 
to the follow-up protocol of the diabetes department, 
microalbumin and creatinine in patients’ morning urine 
samples are analysed every three months. From these, 
patients who had three consecutive urinary albumin 
excretion measurements within the last six months 
were selected. The information about the patients’ 
medical status such as diabetes duration, medication, 
height, and weight were derived from the patient files. 
Morning serum and samples were collected. The serum 
samples were stored at -80ºC until they were tested. 
The patient group was divided into three subgroups 
according to their level of albuminuria calculated us-
ing the urine microalbumin/creatinine ratio. Group 
1 consisted of normoalbuminuric patients who had 
0–30 μg/mg albumin/creatinine ratio (n = 45), group 
2 consisted microalbuminuric patients who had 30– 
–300 μg/mg albumin/creatinine ratio(n = 47), and 
group 3 consisted macroalbuminuric patients who had 
> 300 μg/mg albumin/creatinine ratio (45). 
Analytical methodologies
Galectin-3 was measured by micro-ELISA method 
with Biosensor Human Galectin-3 Platinum Eliza 
reagent (BMS279/4/BMS279/4TEN). The performance 
characteristics of the assay given by the manufacturer 
were as follows; sensitivity 0.29 ng/mL, intra-assay CV 
7.5%, and inter-assay CV 5.4%. HbA1c measurement 
was performed with the NGSP-certified HPLC method 
on a Variant II Turbo (Bio-Rad, USA). Serum creatinine 
and fasting glucose (FPG) were tested using an AU5800 
analyser (Beckman Coulter, USA) with the reagents of 
the same manufacturer. The glomerular filtrate rate 
(GFR) was calculated according to the Cockcroft-Gault 
formula [9].
Statistical analysis
Descriptive statistics were presented as mean ± stand-
ard deviation (SD) and median (2.5–97.5%) as required. 
The comparison of the groups was done with independ-
ent samples Student’s t or Mann-Whitney U test. Cor-
relations between clinical variables and the galectin-3 
were determined by Pearson’s correlation analysis. The 
Krusker-Wallis test was also performed. Multiple regres-
sion analysis was performed to determine the relation 
between galectin-3 and age, body mass index (BMI), 
diabetes duration, (GFR), urinary microalbumin excre-
tion, microalbumin/creatinine ratio, (FPG), HbA1c, and 
serum creatinine. Values of p < 0.05 were considered 
significant. The statistical analyses were performed with 
Medcalc version 15.2.2 statistical software.
The study protocol was approved by the ethics com-
mittee of the hospital. 
Results
The descriptive statistics of the total group and three 
subgroups are presented in Table I. Significant differ-
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ences were observed between GFR results of group 1 
vs. group 3 (p < 0.0001) and group 2 vs. group 3 
(p = 0.0006), and serum creatinine results of group 1 
vs. group 3 (p = 0.0003) and the group 2 vs. group 3 
(p < 0.0001). The three subgroups did not reveal any 
significant difference concerning the age, BMI, dura-
tion of DM, FPG, and HbA1c levels. Krusker-Wallis test 
either did not show any difference between groups 
with regard to age (p = 0.09, BMI (p = 0.12), FPG 
(p = 0.83), HbA1c (p = 0.57), duration of the disease 
(p = 0.76), and galectin-3 levels (p = 0.15). On the other 
hand, GFR and serum creatinine results of group 3 
were significantly different from the results of the other 
groups (p < 0.0001 for both). 
Table II displays the multiple regression analysis of 
galectin with the other parameters. None of the vari-
ables was found to be related to galectin-3 according to 
multiple correlation coefficient or p-values.
The correlation analysis revealed a weak correlation 
between galectin-3 and microalbumin/creatinine (r = 0.19, 
p = 0.02). Galectin-3 was not correlated with any of the 
other variables (Table III). 
Discussion
In addition to the studies on the molecular basis on the 
subject of galectin-3 and DM and renal disease relation, 
recently an increasing number of clinical studies have 
also been performed on this issue [10–12]. In their study 
on renal biopsy specimens, Kikuchi et al. demonstrated 
that the number of galectin-3-positive cells in diabetic 
glomeruli were significantly increased compared with 
other glomerular diseases [13]. They also noted that this 
increase could be induced by DM-related substances, 
such as AGE. Their findings also suggested that galec-
tin-3 expression in glomeruli might be related to DM 
nephropathy, not DM per se. They could not find any 
correlation between galectin-3 expression and glycated 
haemoglobin or duration of DM.
In a study in mice with high-fat diet-induced 
diabetes, transcriptional upregulation of galectin-3/ 
/AGE-Receptör3 in the endothelial cells was shown 
[14]. Since galectin-3 is a component of AGE-receptor 
complex expressed on the surface of renal cells includ-
ing endothelial cells, galectin-3 upregulation could be 
involved in diabetic nephropathy development. 
In this present study we intended principally to 
determine whether galectin-3 could be useful in the 
evaluation of the development of diabetic nephropathy. 
Galectin-3 results did not reveal any significant differ-
ence between the three groups, as shown in Table I. On 
the other hand, we found signs of impairment of renal 
function between the groups; there was a significant 
difference in GFR and serum creatinine levels in group Ta
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3 and the other two groups. These findings might be 
interpreted such that minimal changes in the renal func-
tion were not associated with galectin-3 values. In their 
study, Jin et al. demonstrated a relation between galec-
tin-3 and diabetic complications including nephropathy 
[15]. They found that galectin-3 levels increased with 
the number of complications. The difference between 
that and our study was that they did not separate 
the complication types as retinopathy, nephropathy, 
neuropathy; instead, they evaluated them all together. 
Another difference was that they defined nephropathy 
using 24-hour urinary albumin excretion, whereas we 
determined it with the microalbumin/creatinine ratio 
in spot urine samples. On the other hand, there are 
also studies that did not find any changes in galectin-3 
levels in diabetic nephropathy [8]. 
One of the results of the study was that galectin-3 
levels were weakly correlated with the microalbumin/ 
/creatinine ratio in the whole group (r = 0.19, p = 0.02). 
A study performed on familial Mediterranean fever 
(FMF) patients showed that galectin-3 levels were as-
sociated with proteinuria [16]. There was a significant 
difference between galectin-3 levels of patients with and 
without proteinuria. Although the albuminuria levels of 
our patients were also significantly different, we could 
not find this much significance between groups. The 
mean proteinuria levels of FMF patients were much 
higher than our patients with macroalbuminuria. 
Table II. Multiple regression analysis of galectin with the other parameters
Tabela II. Analiza regresji wielokrotnej związku stężenia galektyny z innymi parametrami
Independent variables Coefficient rpartial t P
(Constant) 10.4432    
Age (year) –0.04405 –0.1392 –1.565 0.1201
BMI [kg/m2] 0.063 0.1574 1.775 0.0783
Duration of DM (Year) 0.03991 0.1164 1.305 0.1943
GFR –0.009624 –0.0641 –0.715 0.4758
FPG [mg/dL] 0.003146 0.05275 0.588 0.5575
HbA1c (NGSP) (%) –0.3157 –0.1288 –1.446 0.1506
Microalbumin/Creatinine [mg/gr] 0.002529 0.09539 1.067 0.288
Serum creatinine [mg/dL] 0.1515 0.02463 0.274 0.7843
Table III. Correlation coefficients between serum galectin-3 concentrations and other parameters
Tabela III. Współczynniki korelacji między stężeniem galektyny-3 w surowicy a innymi parametrami
Microalbumin/Creatinine [mg/gr]
 3–30 30–300 > 300 Total
Number (Female/Male) 45 47 45 137
  (r) P value  (r) P value  (r) P value (r) P value
Age (year) –0.14 0.36 –0.1 0.48 –0.007 0.96 –0.05 0.54
BMI [kg/m2] 0.21 0.16 0.17 0.24 –0.11 0.46 0.16 0.06
Duration of DM (year) –0.05 0.73 0.1 0.49 0.14 0.34 0.08 0.32
FPG [mg/dL] –0.11 0.46 0.13 0.36 –0.17 0.25 –0.03 0.72
HbA1c (NGSP) (%) 0.024 0.87 –0.014 0.92 –0.27 0.07 –0.08 0.334
GFR –0.04 0.79 –0.01 0.92 –0.18 0.24 –0.13 0.12
Serum creatinine [mg/dL] –0.006 0.96 0.02 0.9 0.2 0.18 0.16 0.06
Microalbumin/Creatinine [mg/gr] Mean 0.009 0.95 0.1 0.49 0.17 0.26 0.19 0.02*
Microalbumin/Creatinine [mg/gr] Last –0.045 0.77 0.04 0.76 0.072 0.63 0.15 0.07
Microalbumin –0.11 0.47 0.21 0.16 –0.19 0.21 0.12 0.17
*Results with p < 0.05
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We could not find a relation between galectin-3 
and the other parameters in the regression analysis. 
Serum galectin-3 was not associated with the age, sex, 
FPG, HbA1c, BMI, or duration of diabetes. Despite 
the evidence that galectin-3 might participate in the 
pathogenesis of DM at the level of pancreatic or adi-
pose cells [7], we could not find any relation between 
galectin-3 and glycaemic status. Our results were also 
inconsistent with the study of Weigert et al., who found 
a negative correlation between galectin-3 and glycated 
haemoglobin [8]. However, there are also reports that 
supported our results [15]. We think that further clini-
cal studies are required on the subject of galectin-3 and 
DM disease course, from obesity and insulin resistance 
to complications.
Conclusions
We can assume that serum galectin-3 values are not 
associated with levels of urinary albumin excretion in 
DM patients. We could not find any relation between 
galectin-3 and the parameters of DM such as FPG, 
HbA1c, and duration of the disease. We conclude that 
serum galectin-3 values do not change during minimal 
renal impairment in the course of DM.
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